Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

GUSTO IV-ACS trial

In contrast to the putative superiority of abciximab in PCI, its role in medical stabilization therapy for ACS was seriously challenged by the findings of GUSTO-IV ACS trial, resulting in a Class III (contraindicated) recommendation. On the other hand, small molecules are recommended as Class II indication for medical management of ACS,... [Pg.51]

The GUSTO-IV ACS Investigators. Effect of glycoprotein llb/IIIA receptor blocker abciximab on outcome of patients with acute coronary syndromes without early revascularization the GUSTO-IV ACS randomized trial. Lancet 2001 357 1915-1924. [Pg.55]

See other pages where GUSTO IV-ACS trial is mentioned: [Pg.45]    [Pg.45]    [Pg.56]    [Pg.34]    [Pg.45]    [Pg.45]    [Pg.56]    [Pg.34]    [Pg.43]    [Pg.52]    [Pg.53]    [Pg.308]   
See also in sourсe #XX -- [ Pg.34 ]



SEARCH



GUSTO trial

© 2024 chempedia.info